Study of rhPSMA-7.3 PETCT POSLUMA Scan to Detect Recurrent Prostate Cancer in Men with Negative Prior PET PSMA Imaging

What this Trial Is About

Researchers are evaluating a new imaging technique called rhPSMA-7.3 PETCT also known as POSLUMA to detect prostate cancer in men who have rising prostate-specific antigen PSA levels after previous treatment but showed negative results on their most recent PSMA PET scan. This phase II trial aims to find out if this new scan can better identify biochemically recurrent prostate cancer compared to earlier imaging methods. In this study, participants receive an intravenous injection of the rhPSMA-7.3 tracer and then undergo a PETCT scan 60 minutes later on the first day. PET scans use a small amount of radioactive tracer that highlights tumor cells, while CT scans provide detailed 3D images of the bodys tissues. Combining these scans creates clearer images to help locate cancer cells. After the scan, participants are monitored with follow-up visits at 14 days and then every 3 months for up to 2 years. During the trial, participants will have PETCT imaging and their health records reviewed. Researchers will assess how well the rhPSMA-7.3 PETCT detects cancer, verify findings with pathology or additional imaging, and track any changes in treatment plans based on the scan results. The main measurement is the detection rate over 2 years, and secondary outcomes include verified detection rates and impact on management. Safety and disease progression are also monitored throughout the follow-up period.

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial